Ceramedix Holdings

Ceramedix is a clinical-stage biotechnology company focused on developing first-in-class monoclonal antibodies that target ceramide-mediated signaling. The company's lead therapeutic candidate, 2A2, is a humanized monoclonal antibody designed to prevent endothelial cell apoptosis and subsequent organ damage. This approach is currently being applied to the treatment of Acute Radiation Syndrome (ARS), specifically targeting the gastrointestinal and pulmonary systems. Ceramedix has received substantial funding and support from the Biomedical Advanced Research and Development Authority (BARDA) to advance its radiation countermeasures. Beyond radiation injury, the company is exploring the utility of its anti-ceramide platform in treating sepsis, dermatitis, and other inflammatory conditions. By protecting the vascular endothelium, Ceramedix aims to provide a novel solution for high-unmet-need indications involving systemic microvascular damage.